HDAC6 and Miyoshi myopathy: Similarly to the HDAC6-selective compound ACY-1215 (Figure S8), treatment with Compound 10 led to a marked increase in acetylated α-tubulin levels in MM cell lines, including both drug-sensitive and drug-resistant models (Figure 6).